Biogen Partner Pushing On With Alzheimer's Drug Despi...
The Tokyo-based company’s plans for the second drug come amid renewed scrutiny around the U.S. Food and Drug Administration’s June approval of Aduhelm, which caused resignations among a panel of independent experts who said the therapy was ineffective, and has garnered a call for a federal probe in the U.S. Eisai’s second compound in development to treat Alzheimer’s has the potential for fewer side effects like brain swelling and bleeding and could come in an injection enabling at-home administration, rather than intravenous infusions in hospitals, Ivan Cheung, the Woodcliff Lake, New...
Source: dailymaverick.co.za